CRIA Trials Currently Enrolling
Serostim® for HARS
CRIA has begun enrollment in this multicenter study that follows up on a national level a previous pilot study that CRIA sponsored and conducted. This current 26-week, double-blind, randomized, placebo-controlled study looks at the effectiveness and safety of Serostim® (human growth hormone) when used to treat the abnormal fat distribution that occurs in patients treated with antiviral drugs for HIV infection. Patients with the condition know as HARS (HIV-related adipose redistribution syndrome) often have increased amounts of fat in the abdomen, the upper back, and (especially in women) in the breasts. If you are an adult who is HIV+, are on a stable anti-HIV drug regimen, and have problems with abnormal fat distribution, you may be eligible for the study.
Vigilance II Genotyping Study
You may be eligible for this study if:
You will come in for one blood draw specifically for the study. This blood will be used for the genotyping test. Your personal doctor will get the results of the genotyping test within 7-10 business days and use these results to help choose a drug regimen that may be beneficial to you. We will gather data about your progress (up to one year) from later blood draws by your personal doctor that are part of your regular care. You will be paid $15 after enrolling in the study to cover transportation, lost time from work, or meals. Your insurance company or a state health insurance agency will be billed for the blood tests. If you do not have insurance or state coverage and if you cannot pay for the tests, your study doctor will try to enroll you in a special patient assistance program.
For more information on these studies, please call Dr. Douglas Mendez at (212) 924-3934, ext. 126, or visit our Web site (www.criany.org).
This article was provided by AIDS Community Research Initiative of America. It is a part of the publication CRIA Update. Visit ACRIA's website to find out more about their activities, publications and services.